TheraBionic’s technology is a breakthrough in the war on cancer.
We are transforming patients’ lives through discoveries in bio-electromagnetics to treat cancer.
Our Approach
TheraBionic is an innovative medical device company, and maker of the TheraBionic P1 medical device. The TheraBionic P1 device is FDA approved for treatment of advanced hepatocellular carcinoma (HCC), the most common form of liver cancer in adult patients for whom first and second line therapies have failed.
Safe, effective treatment without the side effects
The TheraBionic P1 device is compact, portable, and easy to use. In multiple studies, patients undergoing treatment using the TheraBionic P1 device did not experience the debilitating side effects associated with other cancer-fighting therapies.
Meet Our Team
-
Boris Pasche, MD, PhD
-
Alexandre Barbault
-
Valerie Pasche, MD
-
Stefan Grant, MD, JD MBA
A powerful tool in patient treatment and care
TheraBionic Inc’s patented, tumor-specific radio frequencies have shown to be effective in tumor shrinkage, blocking new cancer cell growth, and increased overall survival rates.
TheraBionic News and Research
TheraBionic Inc. announces FDA Approval of new medical device to treat advanced liver cancer
TheraBionic’s P1 device is the First FDA-Approved Therapy Using Radiofrequency Electromagnetic Fields for the Systemic Targeted Treatment of Cancer.
Safety and efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma
Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue results in systemic delivery of low and safe levels of RF EMF from head to toe.
Karmanos Cancer Institute first to receive new FDA-approved treatment for advanced liver cancer
Michigan’s largest provider of cancer care and research will be the first provider in the country to offer patients the FDA-approved TheraBionic P1 device.